Research advances in anti-Aβ targeted therapy for Alzheimer's disease: An update
10.3760/cma.j.issn.0254-9026.2019.12.030
- VernacularTitle: 阿尔茨海默病抗Aβ靶向治疗的研究进展
- Author:
Jiyi XU
1
;
Zhi ZHOU
2
;
Bin QIN
1
Author Information
1. Department of Neurology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
2. Department of Geriatrics, China-Japan Friendship Hospital, Beijing 100029, China
- Publication Type:Review
- Keywords:
Alzheimer disease;
Amyloid;
Targeted therapy
- From:
Chinese Journal of Geriatrics
2019;38(12):1441-1444
- CountryChina
- Language:Chinese
-
Abstract:
The theory of amyloid-induced Alzheimer's disease(AD)has been challenged by the scientific community.However, with the deep study of amyloid beta(Aβ)cascade metabolic reaction process and the characteristics and functions of various Aβ polypeptides, people have a profound understanding of the pathogenesis of AD caused by Aβ.Currently, several Aβ antibodies, including the protofibril selective antibody BAN2401, are in clinical trials for treating Alzheimer's disease.After the good results of targeted therapy for Aβ(Ban2401), this theory has attracted our attention again.In this paper, the pathogenesis of Aβ and the progress of targeted therapy were reviewed systematically.
